WINNIPEG, MANITOBA--(MARKET WIRE)--Aug 17, 2007 -- Miraculins Inc. (CDNX:MOM.V - News) (the “Company”), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces an amendment to the previously announced non-brokered private placement offering (the “Offering”). The price per unit has been changed to $0.35 with all other terms and conditions of the Offering remaining unchanged. The Company expects the Offering to close on or about August 24, 2007.
